This document discusses beta blockers and focuses on bisoprolol. It summarizes that:
1) Beta blockers are a class of drugs used to treat heart conditions like heart failure and hypertension, but they have diverse properties. Bisoprolol is a selective beta-1 blocker.
2) Studies show bisoprolol provides similar or better blood pressure control compared to other beta blockers like atenolol and metoprolol. It also provides superior heart rate reduction.
3) The CIBIS II trial found bisoprolol reduced all-cause mortality by 34% in heart failure patients when added to standard therapy of diuretics and ACE inhibitors.
Beta Blockers in current cardiovascular practice Praveen Nagula
betablockers are the drug of choice for prevention of progression of heart failure with mortality benefit, after the evolution of neurohormonal regulation as pathogenesis of heart failure
Beta Blockers in current cardiovascular practice Praveen Nagula
betablockers are the drug of choice for prevention of progression of heart failure with mortality benefit, after the evolution of neurohormonal regulation as pathogenesis of heart failure
Among patients with or at high risk of CVD, use of an FDC strategy for blood pressure, cholesterol, and platelet control vs usual care resulted in significantly improved medication adherence.Polypill therapy significantly improved adherence, SBP and LDL-cholesterol in high risk patients compared with usual care, especially among those who were under-treated at baseline.
Ticagrelor in acute myocardial infarctionVasif Mayan
Potential benefits of dual antiplatelet therapy beyond 1 year after an MI has not been studied
Patients with MI are at increased risk of RECURRENT ISCHAEMIC EVENTS
Intensive secondary prevention is theoretically beneficial
Finding an ideal drug with best risk-benefit ratio is a challenge
TICAGRELOR
--- Direct acting
Not a pro-drug; does not require metabolic activation
Rapid onset of inhibitory effect on the P2Y12 receptor
Greater inhibition of platelet aggregation than clopidogrel
--- Reversibly bound
Degree of inhibition reflects plasma concentration
Faster offset of effect than clopidogrel
Functional recovery of circulating platelets within ~48 hours
PLATO trial
PEGASUS TIMI trial
ARBs (Angiotensin receptor blockers) are the most widely used anti hypertensive throughout the world. A solid knowledge related to ARB will make our practice more patients friendly & benefit will be maximum.
Combination Therapy In Hypertension - Dr Vivek Baliga PresentationDr Vivek Baliga
Dr Vivek Baliga of Baliga Diagnostics, Bangalore, discusses the common combination therapies used in the management of hypertension in clinical practice.
Among patients with or at high risk of CVD, use of an FDC strategy for blood pressure, cholesterol, and platelet control vs usual care resulted in significantly improved medication adherence.Polypill therapy significantly improved adherence, SBP and LDL-cholesterol in high risk patients compared with usual care, especially among those who were under-treated at baseline.
Ticagrelor in acute myocardial infarctionVasif Mayan
Potential benefits of dual antiplatelet therapy beyond 1 year after an MI has not been studied
Patients with MI are at increased risk of RECURRENT ISCHAEMIC EVENTS
Intensive secondary prevention is theoretically beneficial
Finding an ideal drug with best risk-benefit ratio is a challenge
TICAGRELOR
--- Direct acting
Not a pro-drug; does not require metabolic activation
Rapid onset of inhibitory effect on the P2Y12 receptor
Greater inhibition of platelet aggregation than clopidogrel
--- Reversibly bound
Degree of inhibition reflects plasma concentration
Faster offset of effect than clopidogrel
Functional recovery of circulating platelets within ~48 hours
PLATO trial
PEGASUS TIMI trial
ARBs (Angiotensin receptor blockers) are the most widely used anti hypertensive throughout the world. A solid knowledge related to ARB will make our practice more patients friendly & benefit will be maximum.
Combination Therapy In Hypertension - Dr Vivek Baliga PresentationDr Vivek Baliga
Dr Vivek Baliga of Baliga Diagnostics, Bangalore, discusses the common combination therapies used in the management of hypertension in clinical practice.
FINAL.. beta blockers in cardiovascular disease.pptxdkapila2002
beta blockers have an ever increasing role in many cardiovascular disorders like heart failure,heart attacks,hypertension & SIHD. With new_generation beta-blockers,their efficacy has increased with fewer side effects.They now have a very important role in heart-failure & CAD,while lesser role in management of hypertension.Their present status in CV disorders according to latest guidelines is highlighted.The so called thierd generation betablockers have shown better efficacy with fewer side-effects though large scale randomized trials are lacking
Atrioventricular blocks are related to delay in conduction of the AV node..
Their recognition is primarily by ECG, anatomical correlation is by EP study.
ST elevation is not always due to STEMI. Other causes to be kept in mind to prevent the undue complications of thrombolysis. wrong patient and wrong management
The electrocardiogram, a basic tool in cardiology has been developed two centuries ago. It was recorded by a giant machine at that time, which is now being recorded on a mobile. Such is the advancement in ECG, which is still the gold standard in diagnosis of VT .
SGLT2I The paradigm change in diabetes managementPraveen Nagula
Just like ARNI, SGLT2I have changed the face of diabetes management and they have a good profile in multimodality management because of pleiotropic effects
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
3. Outline
Hypertension
Heart failure and its management
Beta Blockers
Beta blocker in hypertension
β-blockers (BB) in HF treatment
ß1-selectivity of Various ß-blockers
Bisoprolol
Clinical Pearls
Summary
4. Beta Blockers
• Beta-blockers refer to a mixed group of drugs with diverse pharmacodynamics and
pharmacokinetic properties.
• They have shown long term beneficial effects on mortality and cardiovascular disease
(CVD) when used in people with heart failure or acute myocardial infarction.
• Beta-blockers were thought to have similar beneficial effects when used as first-line
therapy for hypertension.
Farzam K et al., Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available
8. Heart Failure
HF worldwide prevalence is
>37.7 million, in India it is
around 10 millon.
Annual mortality due to HF in
India is ~0.1 mn to 0.16 mn.
The current estimates
about incidence of HF
in India vary widely
from 1.3 to 23 million.
In International CHF Study, it
was found that heart failure
patients in India had one of the
highest mortality rates after
one year of diagnosis at 23%.
1. Indian Heart J. Jan-Feb 2018;70(1):105-127;
2. J Pract Cardiovasc Sci 2016;2:28-35
Epidemiology Of HF
9. Management Of Heart Failure
Class of drug Example
ACE inhibitors Captopril, Enalapril, Ramipril
ARBs Valsartan, Losartan, Candesartan
ARNI Sacubitril (given with ARB)
Beta blockers Bisoprolol, Metoprolol, Carvedilol
MRA Spironolactone, Eplerenone
Loop Diuretics Furosemide, Torsemide
Thiazide diuretics Hydrochlorothiazide
Other Ivabradine, Digoxin
Interventions: Cardiopulmonary resuscitation – CPR, Cardioversion, PCI, CABG, Pacemaker, Implantable
cardioverter defibrillator (ICD), Left Ventricular Assist Device (LVAD), Heart Transplant
ACE: angiotensin-converting enzyme, ARB: angiotensin receptor blocker, ARNI: angiotensin receptor-neprilysin
inhibitor, MRA: Mineralocorticoid receptor antagonist
16. High prevalence and poor BP control rate across the India
In 2017, prevalence of hypertension in India is 30.7
Fig. Hypertension awareness, treatment, and
control at different study sites
Am J Hypertens (2017) 30 (4): 373-381.
Fig. Hypertension awareness, treatment,
and control at urban and rural locations
17.
18. Am J Cardiol 2010;106:1819 –1825
There are valid reasons to question the utility of certain beta blockers in treating hypertension.
Many of the perceptions about beta blockers are derived from data obtained from studies of traditional
agents or combinations of diuretics and blockers.
There are intrinsic differences among beta blocker class. The vasodilatory beta blockers, which have
generally not been included in comparative meta-analyses, lower blood pressure to a similar degree as
other antihypertensive drugs, may provide better central aortic pressure reductions than traditional
blockers, and are associated with neutral or favorable metabolic effects.
When addressing the question of beta blockers’ effectiveness, the answer lies not in global
generalizations but in assessing individual patients and specific beta blocking agents.
19. For the ischemic patient, be it early or late intervention post-myocardial infarction, or chronic
ischemia in non-surgical and surgical patients, the significant benefits from beta-blockers in
reducing cardiovascular end-points stem from beta-1 blockade.
Likewise for the heart failure patient, on a background of ACE-inhibition, beta-1 blockade (the
common property of carvedilol, metoprolol and bisoprolol) is responsible for the 35% reduction
in all-cause mortality.
Central obesity in younger subjects is linked to endothelial inflammation and
dysfunction, insulin resistance, markedly increased sympathetic nerve activity and
increased cardiac output, heart rate and blood pressure - hemodynamic scenario
ideal for beta-1 blockade
International Journal of Cardiology 120 (2007) 10–27
20. In younger hypertensives beta-blockers reverse both ECG – and echocardiographic – LVH. High
beta-1 selectivity ensures reversibility of echocardiographic LVH at least as great as the action
of ACE-inhibitors.
Beta-blocker-induced metabolic disturbance (lipids, blood sugar and insulin-resistance) stems
from beta-2 blockade (and possibly beta-3 blockade). Such disturbances are avoided by high
beta-1 selectivity, beta-2/3 intrinsic sympathomimetic activity or alpha blockade.
In trials involving younger/middle-aged overweight hypertensives (MRC mild Hypertension,
IPPPSH, MAPHY, UKPDS), with relatively narrow pulse pressures, first-line beta-blockade has
been more effective than placebo and diuretics, and at least as good as ACE-inhibitors, in
preventing coronary events
International Journal of Cardiology 120 (2007) 10–27
21. Elderly systolic hypertensives tend to have low plasma renin activity, insensitive beta-
receptors, low/normal cardiac output and non-compliant arteries (wide pulse pressure).
Such a haemodynamic scenario is unsuited to certain first-line beta-blockers e.g. atenolol
and propranolol.
First-line low-dose diuretic therapy with second-line beta-blocker therapy, has a track
record at least as good as other combination therapies in reducing cardiovascular
events in the elderly hypertensive, with the added bonus of a 30% reduction in the
risk of bone fractures.
Overweight/obesity in the younger/middle-aged hypertensive, and its
accompanying increased sympathetic nerve activity, is a positive indication for beta-1
blockade and not a relative contra-indication.
International Journal of Cardiology 120 (2007) 10–27
22. 2017 The Role of Beta-blockers in Hypertension
Adv Exp Med Biol. 2017;956:149-166.
β-blockers for Hypertension: Are they Going Out of
Style?
24. BB reduce mortality and morbidity in symptomatic patients with HFrEF, despite treatment with an
ACEI and, in most cases, a diuretic, but have not been tested in congested or decompensated
patients.
There is consensus that BB and ACEIs are complementary, and can be started together as soon as the
diagnosis of HFrEF is made.
There is no evidence favouring the initiation of treatment with a BB an ACEI has been started.
BB should be initiated in clinically stable patients at a low dose and gradually up-titrated to the
maximum tolerated dose.
In patients admitted due to acute HF (AHF) BB should be cautiously initiated in hospital, once the
patient is stabilized.
Beta-blockers are recommended in patients with a history of myocardial infarction and
asymptomatic LV systolic dysfunction to reduce the risk of death
European Heart Journal (2016) 37, 2129–
β-blockers (BB) in HF treatment
26. Bisoprolol
Bisoprolol is a cardioselective β1-blocker.
It is used along with other β 1-blockers to treat multiple heart diseases such as congestive heart failure,
without having the unwanted effect of the β2 receptor blocking, which can affect multiple systems in the
body.
Bisoprolol is considered to be one of the selective agents indicated in the treatment plan of compensated
heart failure, along with carvedilol and metoprolol.
Selective β - blockers are considered the first-line treatment for chronic stable angina.
It is also FDA approved for the treatment of hypertension, post, or recent myocardial infarction (MI).
Bazroon AA et al., Treasure Island (FL): StatPearls Publishing; 2021 Jan-.
27. Heart Kidney
Heart Rate Force of
Contraction Secretion of Renin
Beta 1
↑ CO ↑ PR
↑ BP
↑ Work Load on Heart
Heart Failure, LVH
Bisoprolol
Mechanism of Action: Bisoprolol
29. –16.5
–12.4
–14.2
–9.9
–12.2
–10.9
–13.2
–8.9
p = 0.03
0
–5
–10
–15
–20
day
(6 a.m. – 10 p.m.) (6 a.m. – noon)
night
(10 p.m. – 6 a.m.)
last 4 hours
of dosing interval
(6 a.m. – 10 a.m.)
p = 0.03
p = 0.54
p <0.05
mean
change
in
systolic
blood
pressure
(mm
Hg
)
Atenolol ( n = 96)
Bisoprolol ( n = 107)
S ± SEM
BISOPROLOL Vs ATENOLOL
Neutel JM et al. Am J Med 1993; 94:181–187
ABPM technique were used to compare between the bisoprolol (10 to 20 mg OD) and atenolol (50
to 100 mg) for blood pressure reduction
n=203
31. Haasis R et al. Eur Heart J 1987; 8 (Suppl M): 103–113
0
20
40
60
80
100
90%
SBP HR RPP
66%
93%
54%
92%
60%
%
Bisoprolol: 24 H Efficacy In Comparison To Metoprolol
(BISOMET Study)
The effects of the beta blockers on systolic blood pressure, heart rate and rate-pressure product during exercise, 24 h and
3h at rest after administration (p.a.) were compared with the values obtained in the baseline exercise test (El)
Bisoprolol 10 mg
Metoprolol
n = 87
Under Exercise Conditions
32. 180
160
140
120
100
80
90
80
70
60
50
mm Hg SBP
n.s.
DBP
2-4 weeks 0 + 2 + 4 weeks
placebo ß-blocker
p < 0.01
p < 0.05
HR
beats/min
Bisoprolol (n = 44)
Metoprolol (n = 43)
n.s.= not significant
*
*
* *
*
* *
*
*
*
*
BISOMET Study
Haasis R et al. Eur Heart J 1987; 8 (Suppl M): 103–113
At rest
33. Comparison of Bisoprolol to a metoprolol for control heart rate and blood pressure in mild
to moderate hypertensive patients (CREATIVE Study)
Bisoprolol provided superior dynamic HR reduction and non-inferior dynamic BP reduction vs. metoprolol
. No new safety concerns were found.
n=186
Treatment duration: 12 weeks
Hypertens Res. 2017 Jan;40(1):79-86
34. Comparing Beta-Blocking Effects of Bisoprolol, Carvedilol and Nebivolol
• Beta-blocking effi cacy of bisoprolol, carvedilol and nebivolol both at rest and during exercise. In addition, we
also determined potential effects of beta-blockade on quality of life (QOL).
Hemodynamic Effects
-Compared to baseline, heart rate during exercise was decreased at 3hr by bisoprolol (–24%), carvedilol
(–17%) and nebivolol (–15%)
- At the end of 1 week of chronic administration by bisoprolol (–14%), carvedilol (12 h!; –15%) and
nebivolol (–13%)
Quality of Life
Total QOL with carvedilol was slightly but significantly lower than that with placebo, nebivolol and
bisoprolol in all cases.
Cardiology 2006;106:199–206
35. CIBIS II – Cardiac Insufficiency Bisoprolol Study
• Double-blind, placebo-controlled, randomised trial
• 2,647 patients included (NYHA III + IV)
• Bisoprolol administered on top of standard therapy
(diuretic + ACE inhibitor)
• Study Objective
• Primary objective
• All-cause mortality
Lancet. 1999 Jan 2;353(9146):9-13.
• Secondary objectives
Cardiovascular mortality
Hospital admissions
Cardiovascular mortality or cardiovascular hospital
admissions
Permanent treatment withdrawal
36. Survival
34% reduction in all-cause mortality with bisoprolol
1.0
0.8
0.6
0
0 200 400 600 800
Time after inclusion (days)
Survival
Bisoprolol: 156 deaths (n = 1327)
Placebo: 228 deaths (n = 1320)
log rank test, p < 0.0001
Lancet. 1999 Jan 2;353(9146):9-13.
Lancet. 1999 Jan 2;353(9146):9-13.
37. Analysis of time to death
Patients
Unknown cause
of death
Non-cardio-
vascular deaths
Other cardio-
vascular deaths
Myocardial
infarction
Pump
failure
Sudden
death
0.45
(0.27 – 0.74)
0.75
(0.37 – 1.50)
1.17
(0.67 – 2.03)
0.85
(0.31 – 2.34)
83
6%
p=0.0011
48
4%
36
3%
0.56
(0.39 – 0.80)
0.74
(0.48 – 1.14)
Hazard ratio:
(95% CI)
p=0.17
p=0.75
p=0.58
p=0.41
p=0.0012
Bisoprolol (n = 1327)
Placebo (n = 1320)
0
20
40
60
80
100
47
4%
7
1%
8
1%
28
2% 23
2%
14
1%
18
1%
23
2%
49
4%
Lancet. 1999 Jan 2;353(9146):9-13.
38. Main results at a glance
• All-cause mortality (independent of aetiology) by 34% (p<0.0001)
• Sudden death by 44% (p<0.0011)
• All-cause hospital admissions by 20% (p<0.0006)
• Hospital admissions due to worsening heart failure by 36% (p<0.0001)
In the bisoprolol-treated group of patients there was
a reduction in
Lancet. 1999 Jan 2;353(9146):9-13.
39. Study Conclusions
• CIBIS II successfully demonstrated that ß1-selective bisoprolol given in addition to standard therapy
–
• Reduces significantly all-cause mortality and
• All-cause hospitalisation in CHF patients
• Bisoprolol is the first ß-blocker which has proven its efficacy in a single large-scale CHF study with all-
cause mortality as primary objective
• Bisoprolol was as well tolerated as placebo with a permanent treatment withdrawal rate of 15% in
both groups
Lancet. 1999 Jan 2;353(9146):9-13.
40. Monotherapy with beta-blocker
bisoprolol (first 6 mos) 10mg O.D.
n=505
Primary Endpoint: Time-to-the-first-event of combined all-cause mortality and all-cause hospitalization
throughout study.
Secondary Endpoint: Combined primary endpoint at end of monotherapy phase; individual components of
primary endpoint at study end and at end of monotherapy phase.
CIBIS III Trial
Presented at ESC 2005
Monotherapy with ACE-inhibitor enalapril (first
6 mos) 10mg B.I.D.
n=505
1010 patients > 65 years with mild to moderate CHF (NYHA class II or III) and LV ejection fraction < 35% in 3
months prior to randomization, clinically stable CHF for 7 days
Randomized
32% female, mean age 72 years, mean follow-up 1.22 years
13% received aldosterone-receptor blocker and 84% diuretic
Combination beta-blocker and
ACE-inhibitor therapy (6-24 mos)
Circulation. 2005 Oct 18;112(16):2426-35.
Circulation. 2005 Oct 18;112(16):2426-35.
41. CIBIS III Trial Summary
• Among patients with newly diagnosed mild to moderate heart failure, a strategy
of initial treatment with the beta-blocker bisoprolol did not meet the criteria for
non-inferiority in the per-protocol population for death or hospitalization
compared with a strategy of initial treatment with the ACE-inhibitor enalapril.
• Non-inferiority was met in the intent-to-treat population.
• Current guidelines recommend first-line therapy with an ACE-inhibitor after initial
heart failure diagnosis, followed by addition of beta-blocker.
Presented at ESC 2005
Circulation. 2005 Oct 18;112(16):2426-35.
42. Outcomes of major randomized, placebo-controlled trials in patients with heart
failure and reduced ejection fraction
Am J Cardiovasc Drugs (2017) 17:361–373
44. Design and results of the main clinical trials of beta-blockers in heart failure
CV, cardiovascular; HF, heart failure; LVEF, left ventricular ejection fraction; NNT, number needed to treat; NS, not significant; NYHA,
New York Heart Association. All studies analyzed beta-blockers vs placebo, except COMET (carvedilol vs metoprolol tartrate). All risk
reductions are significant, unless otherwise indicated.
* LVEF was not an inclusion criterion, but 36% of patients had a LVEF > 35%; the patients included were older than 70 years of age.
Rev Esp Cardiol. 2019;72(10):844–852
45. Clinical Pearls
Essential hypertension
• Meta analysis has shown that Atenolol does NOT
reduce cardiovascular mortality and morbidity or MI
in patients with uncomplicated HTN (n=17671)
• In another meta analysis (n=105951), β blockers
when compared to other antihypertensive agents do
not reduce MI or mortality and have shown ↑ risk of
stroke in elderly (> 60 yrs) by 16%
• β blockers reduce risk of MI and mortality in patients
with essential HTN with ACS, post MI with
symptomatic/ asymptomatic LV dysfunction
Heart failure
• Bisoprolol, metaprolol (SR) and carvedilol
all have been shown to
- reduce symptoms of HF
-↑ QOL scores in HF
- ↓ risk of death (RRR 30%)
- combined risk of death and
hospitalizations (RRR 40%)
46.
47. Summary
All beta blockers are majorly approved for the treatment of heart failure and hypertension.
They produce unique nitric oxide–mediated vasodilatory effects, lacks intrinsic sympathomimetic activity,
and possess a tolerability profile.
For heart attack survivors, people with angina, or those with heart failure, beta blockers are a must-use
medication because they have been proven to help prevent stroke and other cardiovascular problems.
β‐Blockers have improved survival and are one of the cornerstones in the treatment of ischemic heart
disease; they exert an antianginal effect by reducing the myocardial workload and oxygen demand.
The effects of β‐blockers have been extensively investigated in patients with AMI and the current practice
guidelines also recommend the use of β‐blockers in all patients after AMI unless contraindicated